Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative and broadly enabling pressure-based instruments, consumables and specialty services for the global biopharmaceutical, cosmetics, nutraceutical, agrochemical and food industries. Food and Beverage Reports Financial Results for the First Quarter of 2022, Period Ended March 31, 2022; the company also released a trade update providing guidance for the rest of the year. Key figures from the report include total revenue for the quarter totaling $480,000, down 14% from $560,000 for the first quarter of 2021; instrument sales of $465,000 compared to $553,800 for Q1 2021; and consumables sales for the quarter were $40,000, down 61% from the same period last year. Operational highlights for the company include the announcement of PBIO’s first nanoemulsion manufacturing agreement under its new UST early access program; the announcement of the early access program for the processing of UST nanoemulsions; Ohio State University’s (“OSU”) successful commissioning of PBI’s production-scale BaroShear UST MAX system for enhanced liquid food and beverage processing within its College of Food Sciences , agriculture and the environment; and installation of the company’s UST platform in OSU’s advanced food processing technology pilot plant. “Driven by demand from current and potential customers, and as part of our plan to have the UST platform ready for full-scale commercialization in 2023, we announced the release of an early access program for our UST processing platform late last month,” PBI President and CEO Richard T. Schumacher said in the press release. “In just two weeks since this announcement, we have (i) signed the first-ever agreement to manufacture a product for sale using our breakthrough UST platform for the preparation of high-quality nanoemulsions; (ii) entered into negotiations with several additional groups for UST treatment projects to begin this year (initially in the areas of nutraceuticals and cosmetics); (iii) started developing and expanding the capabilities needed for a successful commercial launch, including upgrades in manufacturing, quality control, project management and logistics; and (iv) started to complement our technical, sales and marketing areas. With the current early breakthroughs and announcements of initial commercialization activities and agreements for our UST platform, our team and business partners are getting more and more excited. . . . The business expects to be profitable and cash flow positive by the end of 2023.”
To view the full press release, visit https://ibn.fm/5fXRM
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative pressure-based solutions for the global life sciences and other industries. PBIO’s products are based on the unique properties of constant hydrostatic (ie static) and alternating (ie pressure cycling technology or “PCT”) pressure. PCT is a patented technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (eg, cell lysis, biomolecule extraction). The main focus of the company is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutic characterization and quality control, soil and plant biology , forensics and anti-bioterrorism applications. In addition, major new market opportunities have arisen in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired patented technology from BaroFold Inc. (the “BaroFold” technology ) to enable market entry into the biopharmaceutical contract services sector, and (2) use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology platform to (i) create nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and for (ii) preparing premium, homogenized, shelf-stable or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBioSciences.com.
NOTICE TO INVESTORS: The latest PBIO news and updates are available from the company’s newsroom at http://ibn.fm/PBIO
InvestorWire is the transfer service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wired broadcast products you’ll need to ensure your next press release grabs your target audience’s attention and stays with you. While our competitors come at you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire covers important announcements. To further extend the visibility of achievements made across a multitude of industries, InvestorWire’s syndication partners have extended digital coverage to include individual broadcasts on websites and financial platforms visited daily by millions of investors.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, California 90046
InvestorWire is part of the InvestorBrandNetwork.